Medscape
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Due to the progressive nature of PD…
Read More
FDA OKs Novel Levodopa-Based Regimen for Parkinson’s
Christeen Roberie
18:33
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). Due to the progressive nature of PD…
